These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34806405)

  • 21. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
    Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
    Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility.
    Cabanas R; Saurez G; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Valle L; Infante M; Avila M; Herrera R; Hechavarria E; Rios M; Fernández A; Lorenzo Luaces P; Crombet Ramos T
    Cancer Biother Radiopharm; 2014 May; 29(4):173-8. PubMed ID: 24784755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.
    Takeda M; Okamoto I; Nishimura Y; Nakagawa K
    Lung Cancer (Auckl); 2011; 2():59-67. PubMed ID: 28210119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety.
    Bernhard W; Barreto K; El-Sayed A; Gonzalez C; Viswas RS; Toledo D; Casaco A; DeCoteau J; Fonge H; Geyer CR
    BMC Cancer; 2021 Mar; 21(1):270. PubMed ID: 33711962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease.
    de Castro-Suárez N; Rodríguez-Vera L; Villegas C; Dávalos-Iglesias JM; Bacallao-Mendez R; Llerena-Ferrer B; Leyva-de la Torre C; Lorenzo-Luaces P; Troche-Concepción M; Ramos-Suzarte M
    J Clin Pharmacol; 2019 Jun; 59(6):863-871. PubMed ID: 30633365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Near infrared fluorescence imaging of EGFR expression
    Bernhard W; El-Sayed A; Barreto K; Gonzalez C; Hill W; Parada AC; Fonge H; Geyer CR
    Oncotarget; 2018 Jan; 9(5):6213-6227. PubMed ID: 29464066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck.
    Crombet Ramos T; Mestre Fernández B; Mazorra Herrera Z; Iznaga Escobar NE
    Front Oncol; 2020; 10():817. PubMed ID: 32537431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of
    Suman S; Priya R; Kameswaran M
    Int J Radiat Biol; 2020 Sep; 96(9):1144-1156. PubMed ID: 32657634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
    Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
    Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nimotuzumab: beyond the EGFR signaling cascade inhibition.
    Mazorra Z; Chao L; Lavastida A; Sanchez B; Ramos M; Iznaga N; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):18-26. PubMed ID: 30318080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR.
    Basavaraj C; Sierra P; Shivu J; Melarkode R; Montero E; Nair P
    Cancer Biol Ther; 2010 Oct; 10(7):673-81. PubMed ID: 20647773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
    Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
    Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab.
    Garrido G; Rabasa A; Garrido C; Chao L; Garrido F; García-Lora ÁM; Sánchez-Ramírez B
    Front Pharmacol; 2017; 8():595. PubMed ID: 29056908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidized tea polyphenol (OTP-3) targets EGFR synergistic nimotuzumab at inhibition of non-small cell lung tumor growth.
    Huang Y; Cuan X; Yang X; Zhu W; Zhao Y; Jiang L; Zi C; Wang X; Sheng J
    Bioorg Chem; 2022 Nov; 128():106084. PubMed ID: 35970070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
    Cetina L; Crombet T; Jiménez-Lima R; Zapata S; Ramos M; Avila S; Coronel J; Charco E; Bojalil R; Astudillo H; Bazán B; Dueñas-González A
    Cancer Biol Ther; 2015; 16(5):684-9. PubMed ID: 25802932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
    Liang R; Yang L; Zhu X
    Cancer Control; 2021; 28():1073274821989301. PubMed ID: 33504193
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.